Word

SEQUENCEFOUR

Status

Pending

Status Code

653

Status Date

Tuesday, December 12, 2023

Serial Number

97694840

Mark Type

4000

Filing Date

Monday, November 28, 2022

Trademark Owner History

CureVac RNA Printer GmbH

Classifications

40 Custom synthesis of chemical compounds, namely, biological macromolecules, to the order and specifications of others

9 Laboratory apparatus and instruments, namely, pre-packed columns for use in chemical synthesis; mobile laboratory robots with artificial intelligence for use in scientific, diagnostic and pharmaceutical research and for use in pharmaceutical production and laboratory automation; mobile device for the synthesis of macromolecules, namely, for therapeutic and preventive treatment of tumor diseases, infectious diseases, autoimmune disorders and allergies, for treatment of inherited genetic diseases or for protein or enzyme replacement therapy, and for treatment of neurological, neuromuscular, neurodegenerative and cardiovascular diseases, and for treatment of metabolic disorders; Mobile production station of biological macromolecules, namely, for therapeutic and preventive treatment of tumor diseases, infectious diseases, autoimmune disorders and allergies, for treatment of inherited genetic diseases or for protein or enzyme replacement therapy, and for treatment of neurological, neuromuscular, neurodegenerative and cardiovascular diseases, and for treatment of metabolic disorders; bioreactors for growing cells

7 Machines for use in chemical or biopharmaceutical industry, namely for the synthesis of macromolecules; Bioreactors for the synthesis of macromolecules; Filling machines, in particular for use for filling biopharmaceutical compositions into containers; Industrial robots

5 Chemical preparations for medical use, namely, biological macromolecules, namely, for therapeutic and preventive treatment of tumor diseases, infectious diseases, autoimmune disorders and allergies, for treatment of inherited genetic diseases or for protein or enzyme replacement therapy, and for treatment of neurological, neuromuscular, neurodegenerative and cardiovascular diseases, and for treatment of metabolic disorders; Pharmaceutical and veterinary preparations for medical and veterinary use; Pharmaceuticals and medicines based on biological macromolecules for the treatment of neurological, neuromuscular, neurodegenerative and cardiovascular diseases, for treatment or prevention of infectious diseases, allergies, autoimmune disorders and tumor diseases, for treatment of metabolic disorders and for treatment of inherited genetic diseases or for protein or enzyme replacement therapy; Gene therapeutic preparations; Dietetic substances adapted for medical use, in particular substances for food supplements; Vaccines

1 Chemicals and biomolecules, namely, biological macromolecules, for industrial or scientific purposes other than for medical or veterinary purposes; Reagents for research purposes; Reagents for use in scientific apparatus for chemical or biological analysis and/or synthesis

44 Medical and veterinary services, in particular for therapeutic and preventive treatment of tumour diseases, infectious diseases, autoimmune disorders and allergies, for treatment of inherited genetic diseases or for protein or enzyme replacement therapy, and for treatment of neurological, neuromuscular, neurodegenerative and cardiovascular diseases, and for treatment of metabolic disorders; Vaccination

42 Scientific and technological services and research, in particular for identification, testing and characterisation of biological molecules; pre-clinical and clinical testing of macromolecules

SEQUENCE FOUR

Trademark Events

Dec 12, 2023

Notification Of Letter Of Suspension E-Mailed

Dec 12, 2023

Letter Of Suspension E-Mailed

Dec 12, 2023

Suspension Letter Written

Dec 12, 2023

Teas/Email Correspondence Entered

Dec 11, 2023

Correspondence Received In Law Office

Dec 11, 2023

Teas Response To Office Action Received

Sep 9, 2023

Notification Of Non-Final Action E-Mailed

Sep 9, 2023

Non-Final Action E-Mailed

Sep 9, 2023

Non-Final Action Written

Sep 6, 2023

Assigned To Examiner

Dec 21, 2022

New Application Office Supplied Data Entered

Dec 1, 2022

New Application Entered